All News #Library
Rare Diseases
OSE Immunotherapeutics Picks Lusvertikimab for Chronic Diseases
29 Jan 2026 //
GLOBENEWSWIRE
OSE Immunotherapeutics Welcomes FDA Orphan Designation
21 Jan 2026 //
GLOBENEWSWIRE

Market Place
Sourcing Support